Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Terlipressin intravenous - Orphan Therapeutics

Drug Profile

Terlipressin intravenous - Orphan Therapeutics

Alternative Names: Lucassin

Latest Information Update: 13 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orphan Therapeutics LLC
  • Developer Mallinckrodt plc; Orphan Therapeutics
  • Class Antidiuretics; Antihaemorrhagics; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatorenal syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatorenal syndrome

Most Recent Events

  • 11 Nov 2019 Mallinckrodt announces intention to submit NDA to US FDA for Hepatorenal Syndrome in first half of 2020
  • 11 Nov 2019 Adverse events and efficacy data from the phase III CONFIRM trial in Hepatorenal Syndrome released by Mallinckrodt
  • 15 Aug 2019 Top-line efficacy data from a phase III CONFIRM trial in Hepatorenal Syndrome released by Mallinckrodt
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top